Spravato® (esketamine) has become an important treatment option for adults with treatment-resistant depression, offering hope for individuals who haven’t improved with traditional antidepressants. One of the most common questions patients ask is whether there are age requirements for receiving Spravato.

This guide explains minimum age requirements, how FDA guidelines affect eligibility, considerations for younger and older adults, brain development factors, and insurance coverage—all specifically tailored to Spravato (intranasal esketamine), the only FDA-approved ketamine-based treatment for depression.

Key Takeaways

• Spravato is FDA-approved only for adults 18 and older.

• Age rules exist to protect developing brains, which continue maturing into the mid-20s.

• There is no official upper age limit—many older adults tolerate Spravato well.

• Insurance typically covers Spravato for adults meeting treatment-resistant depression criteria.

• Spravato must be administered in a certified clinic with safety monitoring.

• Aurora Wellness offers FDA-approved Spravato, handles all insurance coordination, and provides treatment in a welcoming environment.

  
  

Why Age Matters in Spravato Treatment

Spravato is an FDA-approved nasal spray form of esketamine, used in combination with an oral antidepressant for:

• Treatment-resistant depression (TRD)

• Major depressive disorder with acute suicidal ideation or behavior (MDSI)

Unlike other forms of ketamine treatment (such as IV, IM, or at-home lozenges), Spravato is the only formulation approved by the FDA, and therefore the only form widely covered by insurance.

Because Spravato interacts with the glutamate/NMDA receptor system, which plays a role in neuroplasticity and brain development, age considerations are important for safety, particularly in younger patients whose brains are still maturing.

Spravato and Brain Development

The human brain continues developing into the mid-20s, especially in areas responsible for:

• Emotional regulation

• Executive functioning

• Decision-making

• Stress response

Spravato’s mechanism—which promotes neuroplasticity—can affect these systems. While this is beneficial for adults with depression, developing brains may be more sensitive, which is why the FDA restricted approval to adults 18+.

Spravato works differently from SSRIs. While SSRIs influence serotonin pathways, Spravato targets glutamate pathways, helping strengthen neural connections and support improved mood regulation.

What Is the Minimum Age for Spravato Treatment?

✔ FDA Minimum Age: 18 Years Old

Spravato is FDA-approved only for adults, meaning:

• Clinics must follow REMS (Risk Evaluation and Mitigation Strategy) guidelines

• Insurance coverage follows FDA rules

• Under-18 treatment is not standard or recommended

At Aurora Wellness, we follow FDA approval standards, meaning we only administer Spravato to adults age 18 and older.

What About Patients Under 18?

Some treatments for adolescents (like traditional antidepressants) are approved, but Spravato is not.
Adolescent esketamine use would be considered experimental, with limited evidence, and is not covered by insurance. Because of this, and due to safety considerations, Spravato treatment is reserved for adults only.

Is There a Maximum Age Limit?

✔ No Upper Age Limit

Many older adults respond well to Spravato, and some even tolerate it better than traditional antidepressants, which may cause:

• Dizziness

• Hyponatremia

• Medication interactions

• Increased fall risk

Spravato tends to have short-lasting side effects (e.g., dissociation, dizziness) that resolve during the required 2-hour monitoring period.

Considerations for Older Patients

A clinician may evaluate the following among many other factors:

• Blood pressure stability

• Cardiovascular history

• Balance and fall risk

• Medication interactions

How Often Is Spravato Given?

Spravato requires regular in-clinic sessions, each followed by a 2-hour monitoring period, as mandated by the FDA and REMS program.

Why FDA Guidelines Matter

The FDA approval for Spravato applies specifically to:

• Adults 18+

• Intranasal esketamine

• Administration only in a certified clinical setting

• Use alongside an oral antidepressant

• Conditions meeting TRD or MDSI criteria

Because this treatment is heavily regulated, insurance companies follow FDA guidelines closely.

Insurance and Age-Based Eligibility

Most insurers—including Medicare and commercial plans—cover Spravato for adults who:

• Are 18 or older

• Have tried at least two antidepressants without adequate improvement

• Have a qualifying diagnosis (TRD or MDSI)

• Are receiving treatment at a REMS-certified clinic

Patients Under 18

Insurance almost never covers Spravato for minors, because:

• It is not FDA-approved

• Safety data is limited

Safety and Monitoring Across Age Groups

Regardless of age, Spravato requires:

• Pre-treatment evaluation

• Blood pressure monitoring

• Observation in a certified clinic for 2 hours

• A safe ride home afterward

But all care occurs in a controlled medical environment, which significantly enhances safety.

Insurance Coverage in New York

Most major insurance plans in New York—including UHC, Aetna, Cigna, BCBS, and Medicare—cover Spravato for adults who meet criteria.

Aurora Wellness helps patients:

• Verify coverage

• Gather required documentation

• Navigate appeals if needed

  
  

Taking the Next Step

Understanding Spravato’s age requirements helps individuals determine whether this FDA-approved treatment may be appropriate for them or a family member.

Spravato offers real hope for adults whose depression hasn’t improved with standard medications. At Aurora Wellness, we guide patients through every step of the proce